Test Information

Test performed at NeoGenomics California, 31 Columbia, Aliso Viejo, CA 92656

Patient Report

Patient's report continues on following page(s).
Molecular Genetics
MET Exon 14 Deletion Analysis

Client: ARUP Laboratories

Patient Name: [Redacted]
Patient DOB / Sex: [Redacted] F
Specimen Type: Unknown
Body Site: Lung
Specimen ID: 22336161958
MRN: [Redacted]
Other Patient ID / Account Number: [Redacted]
Reason for Referral: diagnosis

Ordering Physician(s): [Redacted]
Treating Physician(s): [Redacted]
Accession / Case Number: [Redacted]
Collection Date: 12/20/2022 09:37:00 AM
Received Date: 12/20/2022 02:26:50 PM EST
Report Date: 12/20/2022 02:29:32 PM EST

Results:

<table>
<thead>
<tr>
<th>Test / Panel</th>
<th>MoDX CPT</th>
<th>AMA CPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET Exon 14 Deletion Analysis</td>
<td>81479</td>
<td>81479</td>
</tr>
</tbody>
</table>

Clinical Significance:
Recurrent somatic splicing site alterations at MET exon 14 (METex14) that result in exon skipping and MET activation have been characterized. METex14 mutations are detected most frequently in lung adenocarcinomas (2%), also frequently in other lung neoplasms (2.3%), gliomas (5.4%), and tumors of unknown primary origin (6.4%). Tumors with METex14 alterations may respond to MET inhibitor therapy capmatinib or tepotinib.

Methodology:
The MET exon 14 deletion assay is a real-time polymerase chain reaction (RT-PCR) assay performed using RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissue. Two separate one-step RT-PCR reactions, a wild type (WT) MKK and a deletion MKK are amplified from the same RNA sample. Sample quantity and quality can substantially affect a PCR reaction.

References:

Electronic Signature:
The Analyzing Component of this test was performed at NeoGenomics HQ, 9490 NeoGenomics Way, Fort Myers, FL; 33901 / 866-776-5907 / CLIA #062235950 / Medical Director(s): Anshul Nigrooi, MD. The Technical Component Processing and Analysis of this test was completed at NeoGenomics California, 31 Columbia, Aliso Viejo, CA; 92656 / 855-776-5907 / CLIA #052121050 / Medical Director(s): Radoslav Ganchev, MD. The Professional Component of this test was completed at NeoGenomics HQ, 9490 NeoGenomics Way, Fort Myers, FL; 33901 / 866-776-5907 / CLIA #062235950 / Medical Director(s): Anshul Nigrooi, MD.

The performance characteristics of this test have been determined by NeoGenomics Laboratories. This test has not been approved by the FDA. The FDA has determined such clearance or approval is not necessary. This laboratory is CLIA certified to perform high complexity clinical testing. Images that may be included within this report are representative of the patient but not all testing in its entirety and should not be used to render a result.

The CPT coding provided with our test descriptions are based on MMA and AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

© 2022 NeoGenomics Laboratories, Inc. All rights reserved. NeoGenomics Laboratories and the associated logo are trademarks of NeoGenomics Laboratories, Inc.